Podcasts about amikacin

  • 10PODCASTS
  • 13EPISODES
  • 19mAVG DURATION
  • ?INFREQUENT EPISODES
  • Feb 27, 2024LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about amikacin

Latest podcast episodes about amikacin

eCritCare Podcast
# Epi 121 - AMIKINHAL Trial - Inhaled Amikacin to prevent Ventilator associated pneumonia

eCritCare Podcast

Play Episode Listen Later Feb 27, 2024 27:10


In this episode, we discuss the recently published RCT AMIKINHAL, which tested the efficacy of inhaled amikacin in preventing VAP in ICU patients who were ventilated for> 72 hours. Although, this trail demonstrated reduced incidence of VAP in intervention arm, it's premature to adopt these practices widely in intensive care.

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast
866: Can 3 Days of Inhaled Amikacin Prevent VAP?

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Play Episode Listen Later Nov 2, 2023 3:29


Show notes at pharmacyjoe.com/episode866. In this episode, I’ll discuss inhaled amikacin to prevent VAP. The post 866: Can 3 Days of Inhaled Amikacin Prevent VAP? appeared first on Pharmacy Joe.

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast
866: Can 3 Days of Inhaled Amikacin Prevent VAP?

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Play Episode Listen Later Nov 2, 2023 3:29


Show notes at pharmacyjoe.com/episode866. In this episode, I’ll discuss inhaled amikacin to prevent VAP. The post 866: Can 3 Days of Inhaled Amikacin Prevent VAP? appeared first on Pharmacy Joe.

CCO Infectious Disease Podcast
Emerging Scientific Data and Unique Clinical Scenarios in People With NTM Lung Disease

CCO Infectious Disease Podcast

Play Episode Listen Later Oct 31, 2023 21:24


In this episode, Shannon Kasperbauer, MD, discusses guideline-based treatment recommendations for people with M. abscessus, including a discussion of:Macrolide resistancePredictors for disease progression2020 NTM guideline recommended treatment optionsEmerging therapiesWe will also hear from a patient who describes how she remained adherent during long courses of treatment for M. abscessus.Finally, we hear Dr Kasperbauer discuss a patient case with her colleagues, Charles L. Daley, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G

CCO Infectious Disease Podcast
Guidelines-Based Treatment for NTM Lung Disease: Application in Complex Patients

CCO Infectious Disease Podcast

Play Episode Listen Later Oct 31, 2023 27:08


In this episode, Charles L. Daley, MD, discusses guideline-based treatment recommendations for nontuberculous mycobacterial (NTM) lung disease, including treatment regimens for:Mycobacterium avium complexM. kansasiiM. xenopiWe will also hear from a patient who describes the use of airway clearance devices and a patient who describes his typical NTM treatment course.Finally, we hear Dr. Daley discuss a patient case with his colleagues, Shannon Kasperbauer, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G 

PCE
Key Concepts and Updates for the Diagnosis and Management of NTM-LD

PCE

Play Episode Listen Later Jan 10, 2023 14:04


This podcast episode is part of a multimedia program reviewing the management of nontuberculous mycobacterial lung disease (NTM-LD). Tune in to hear Jennifer Faber-Gerling, RN, MS, CNS, ANP-BC, and Anne O'Donnell, MD, highlight the diagnostic criteria and optimal treatment strategies in patients with NTM-LD. The overview will include: Recommended assessments and tests to appropriately diagnosis NTM-LD in patientsA summary of the current guidelines for the management of NTM-LD, including appropriate monitoring of medications.Guidance on how to individualize treatment plans for patients with NTM-LD based on disease and patient characteristicsPresenters: Jennifer Faber-Gerling, RN, MS, CNS, ANP-BCNurse PractitionerDivision of Mycobacterial and Respiratory InfectionsNational Jewish HealthDenver, ColoradoAnne O'Donnell, MDProfessor of MedicineDivision of Pulmonary, Critical Care, and Sleep MedicineGeorgetown University Medical CenterWashington, DCTo view other program offerings, including a CE-certified on-demand webcast, a Q&A text module, and to download slides, visitpce.is/NTM.

ER-Rx: An ER + ICU Podcast
Episode 80- One-time aminoglycosides for cystitis

ER-Rx: An ER + ICU Podcast

Play Episode Listen Later Oct 20, 2022 6:24 Transcription Available


Let's revive an old practice that may one day help you treat uncomplicated cystitis without having to admit your patient to the hospital Click HERE to leave a review of the podcast!Subscribe HERE!References:All references for Episode 80 are found on my Read by QxMD collectionDisclaimer: The information contained within the  ER-Rx podcast episodes, errxpodcast.com, and the @errxpodcast Instagram page is for informational/ educational purposes only, is not meant to replace professional medical judgement, and does not constitute a provider-patient relationship between you and the authors. Information contained herein may be accidentally inaccurate, incomplete, or outdated, and users are to use caution,  seek medical advice from a licensed physician, and consult available resources prior to any medical decision making. The contributors of the ER-Rx podcast are not affiliated with, nor do they speak on behalf of,  any medical institutions, educational facilities, or other healthcare programs.Support the show

infectious diseases one time uti urinary tract infections cystitis gentamicin references all amikacin tobramycin
Equine Veterinary Journal Podcasts
EVJ On the Hoof Podcast, No. 17, October 2020 - Amikacin induces rapid dose-dependent apoptitic cell death

Equine Veterinary Journal Podcasts

Play Episode Listen Later Oct 6, 2020 7:29


This podcast discusses the paper 'Amikacin induces rapid dose-dependent apoptitic cell death in equine chrondrocytes and synovial cells in vitro’ by Pezzanite et al. 

Out of the Blue: An AJRCCM Podcast
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease

Out of the Blue: An AJRCCM Podcast

Play Episode Listen Later Aug 10, 2017 13:28


Dr. John Fleetham sits down with Dr. Kennth Olivier to discuss the findings of his paper published in the AJRCCM this past March

Cystic Fibrosis Review
Volume 6, Number 10

Cystic Fibrosis Review

Play Episode Listen Later Sep 15, 2016 24:29


Pseudomonas aeruginosa Eradication and Outcomes: Key Questions

AHEAD OF THE CURVE: Cystic Fibrosis
July 2012: Volume 3, Number 12

AHEAD OF THE CURVE: Cystic Fibrosis

Play Episode Listen Later Jul 23, 2012 41:11


eCystic Fibrosis Review: Featured Cases: Emerging Pathogens in Cystic Fibrosis

Medizinische Fakultät - Digitale Hochschulschriften der LMU - Teil 05/19
Imipenem in der intravenösen antibiotischen Prophylaxe und Therapie der experimentellen Endophthalmitis durch Staphylococcus aureus

Medizinische Fakultät - Digitale Hochschulschriften der LMU - Teil 05/19

Play Episode Listen Later Dec 15, 2005


Trotz der üblichen prophylaktischen Maßnahmen im Rahmen der Operationsvorbereitung können Erreger nachgewiesenermassen während der Operation ins Auge gelangen. Die perioperative systemische Gabe von Imipenem kann eventuell ins Augeninnere gelangte Erreger sterilisieren, zumindest bis zu einem bestimmten Maximum an Organismen. Im ersten Teil der vorliegenden Arbeit im tierexperimentellen Modell am phaken Kaninchenauge war es möglich, sämtliche mit 100 CFU S. aureus inifizierten Augen zu sterilisieren, falls diese 8 Stunden und eine halbe Stunde vor Infektion, sowie 8 Stunden nach Infektion intravenös Imipenem erhielten. Bei einer Erregermenge von 10 000 CFU waren noch 5 von 6 Augen steril, bei 10 000 CFU nur noch 3 von 6 Augen. Weiterhin scheint es möglich, den Glaskörper durch alleinige intravenöse Imipenemgabe sterilisieren zu können, wenn eine bestimmte Anzahl von intraokulären Keimen nicht überschritten wird. Im zweiten Teil dieser Arbeit wurden Augen mit 1000 CFU S. aureus infiziert und nach 24 Stunden intravenöse Therapie mit Imipenem oder der in der EVS verwendeten Kombination Ceftazidim und Amikazin begonnen. Nach 7 Tagen waren signifikant geringere Erregermengen in den mit Imipenem behandelten Augen festzustellen, als in mit Ceftazidim und Amikazin behandelten oder der unbehandelten Kontrollgruppe. 4 von 6 mit Imipenem therapierten Augen waren zu diesem Zeitpunkt steril. Ob es möglich ist, eine Endophthalmitis in einem derart frühen Stadium zu diagnostizieren und dann intravenös ohne intraokuläre Antibiotikaeingabe befriedigend therapieren zu können ist jedoch fraglich, denn in dieser Studie waren selbst in Augen mit negativem Kulturergebniss massive Entzündungszeichen festzustellen. Im dritten Teil dieser Arbeit stellte sich die intraokuläre Eingabe von Vancomycin und Amikacin als der alleinigen systemischen Imipenemgabe deutlich überlegen heraus, sowohl im Hinblick auf Erregermengen, klinischen Verlauf und histopathologisches Erscheinungsbild. Zu einem frühen Zeitpunkt der Infektion gegeben, können intraokuläres Vancomycin und Amikacin in diesem Tierexperiment relativ klare optische Medien ohne zusätzlich chirurgische Therapie erhalten. In dem hier durchgeführten Experiment erbrachte die zusätzliche intravenöse Therapie mit Imipenem keine messbare Verbesserung gegenüber der alleinigen intravitrealen Therapie mit Vancomycin und Amikacin.

Cystic Fibrosis Review
July 2012: Volume 3, Number 12

Cystic Fibrosis Review

Play Episode Listen Later Dec 31, 1969 41:11


Featured Cases: Emerging Pathogens in Cystic Fibrosis